CRISPR/Cas9 is a versatile genome-editing technology that is widely used for studying the functionality of genetic elements, creating genetically modified organisms as well as preclinical research of genetic disorders. However, the high frequency of off-target activity (≥50%)-RGEN (RNA-guided endonuclease)-induced mutations at sites other than the intended on-target site-is one major concern, especially for therapeutic and…
Molecular Therapy — Nucleic Acids Template
Write in a clean editor, then format for Molecular Therapy — Nucleic Acids in one click — DocuGuru applies the official Elsevier template with numbered references and exports a submission-ready PDF plus the editable LaTeX source. Free to start.
About the Molecular Therapy — Nucleic Acids format
Molecular Therapy — Nucleic Acids is a peer-reviewed journal published by Elsevier, covering RNA Interference and Gene Delivery, MicroRNA in disease regulation, Cancer-related molecular mechanisms research.
| Publisher | Elsevier |
|---|---|
| Reference style | Numbered (Elsevier) Numbered — [1], [2] in the text [1] A. Smith, B. Jones, C. Lee, A representative article title, Molecular Therapy — Nucleic Acids 12 (2023) 45–58.
Formats any DOI in Molecular Therapy — Nucleic Acids style. No sign-up. |
| Publishes research in | RNA Interference and Gene Delivery MicroRNA in disease regulation Cancer-related molecular mechanisms research CRISPR and Genetic Engineering Circular RNAs in diseases |
| ISSN | 2162-2531 |
| Citation impact (2-yr) | 4.74 |
| h-index | 130 |
| i10-index | 2,215 |
| Total citations | 117,949 |
| Article processing charge | $3,900 |
| Open access | Yes |
| Top institutions publishing here | Inserm |
| Journal website | www.sciencedirect.com |
| You get | A submission-ready PDF and the editable LaTeX source — ready to submit. |
Papers published in Molecular Therapy — Nucleic Acids per year
Citation impact of Molecular Therapy — Nucleic Acids by publication year
Citations each year’s papers have accumulated so far — the most recent years are still building up.
Most-cited papers in Molecular Therapy — Nucleic Acids
Discovered a little over two decades ago, small interfering RNAs (siRNAs) and microRNAs (miRNAs) are noncoding RNAs with important roles in gene regulation. They have recently been investigated as novel classes of therapeutic agents for the treatment of a wide range of disorders including cancers and infections. Clinical trials of siRNA- and miRNA-based drugs have…
mRNA vaccines have the potential to tackle many unmet medical needs that are unable to be addressed with conventional vaccine technologies. A potent and well-tolerated delivery technology is integral to fully realizing the potential of mRNA vaccines. Pre-clinical and clinical studies have demonstrated that mRNA delivered intramuscularly (IM) with first-generation lipid nanoparticles (LNPs) generates robust…
In the past few years, therapeutic microRNA (miRNA) and small interfering RNA (siRNA) are some of the most important biopharmaceuticals that are in commercial space as future medicines. This review summarizes the patents of miRNA- and siRNA-based new drugs, and also provides a snapshot about significant biopharmaceutical companies that are investing for the therapeutic development…
Lipid nanoparticles (LNP) are the leading systems for in vivo delivery of small interfering RNA (siRNA) for therapeutic applications. Formulation of LNP siRNA systems requires rapid mixing of solutions containing cationic lipid with solutions containing siRNA. Current formulation procedures employ macroscopic mixing processes to produce systems 70-nm diameter or larger that have variable siRNA encapsulation…